P
Peter Dubsky
Researcher at Medical University of Vienna
Publications - 149
Citations - 8204
Peter Dubsky is an academic researcher from Medical University of Vienna. The author has contributed to research in topics: Breast cancer & Cancer. The author has an hindex of 38, co-authored 142 publications receiving 6882 citations.
Papers
More filters
Journal ArticleDOI
Endocrine Therapy plus Zoledronic Acid in Premenopausal Breast Cancer
Michael Gnant,Brigitte Mlineritsch,Walter Schippinger,G. Luschin-Ebengreuth,Sabine Pöstlberger,Christian Menzel,Raimund Jakesz,Michael Seifert,Michael Hubalek,Vesna Bjelic-Radisic,Hellmut Samonigg,C. Tausch,Holger Eidtmann,Guenther G. Steger,Werner Kwasny,Peter Dubsky,M. Fridrik,Florian Fitzal,Michael Stierer,Ernst Rücklinger,Richard Greil +20 more
TL;DR: The addition of zoledronic acid to adjuvant endocrine therapy improves disease-free survival in premenopausal patients with estrogen-responsive early breast cancer.
Journal ArticleDOI
De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017
Giuseppe Curigliano,Harold J. Burstein,Eric P. Winer,Michael Gnant,Peter Dubsky,Sibylle Loibl,Marco Colleoni,Meredith M. Regan,Martine Piccart-Gebhart,H.-J. Senn,Beat Thürlimann,Fabrice Andre,José Baselga,Jonas Bergh,Hervé Bonnefoi,Sara Y. Brucker,Fatima Cardoso,Lisa A. Carey,Eva Ciruelos,Jack Cuzick,Carsten Denkert,A. Di Leo,Bent Ejlertsen,Prudence A. Francis,Viviana Galimberti,Judy Garber,Bahadir M. Gulluoglu,Pamela J. Goodwin,Nadia Harbeck,Daniel F. Hayes,Chiun-Sheng Huang,Jens Huober,H. Khaled,Jacek Jassem,Zefei Jiang,Per Karlsson,Monica Morrow,Roberto Orecchia,Kent Osborne,Olivia Pagani,Ann H. Partridge,Kathleen I. Pritchard,Jungsil Ro,Emiel J. Th. Rutgers,Felix Sedlmayer,Vladimir Semiglazov,Zhimin Shao,I.E. Smith,Masakazu Toi,Andrew Tutt,Giuseppe Viale,Toshihiro Watanabe,Timothy J. Whelan,Bo Xu +53 more
TL;DR: The 15th St. Gallen International Breast Cancer Conference 2017 in Vienna, Austria reviewed substantial new evidence on loco-regional and systemic therapies for early breast cancer, and recommended bisphosphonate use in postmenopausal women to prevent breast cancer recurrence.
Journal ArticleDOI
A New Molecular Predictor of Distant Recurrence in ER-Positive, HER2-Negative Breast Cancer Adds Independent Information to Conventional Clinical Risk Factors
Martin Filipits,Margaretha Rudas,Raimund Jakesz,Peter Dubsky,Florian Fitzal,Christian F. Singer,Otto Dietze,Richard Greil,Andrea Jelen,Paul Sevelda,Christa Freibauer,Volkmar Müller,Fritz Jänicke,Marcus Schmidt,Heinz Kölbl,Achim Rody,Manfred Kaufmann,Werner Schroth,Hiltrud Brauch,Matthias Schwab,Peter Fritz,Karsten Weber,Inke Sabine Feder,Guido Hennig,Ralf Kronenwett,Mathias Gehrmann,Michael Gnant +26 more
TL;DR: A gene expression signature predicting the likelihood of distant recurrence in patients with estrogen receptor–positive, HER2-negative breast cancer treated with adjuvant endocrine therapy is developed and validated.
Journal ArticleDOI
Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial
Michael Gnant,Brigitte Mlineritsch,Herbert Stoeger,G. Luschin-Ebengreuth,Dietmar Heck,Christian Menzel,Raimund Jakesz,Michael Seifert,Michael Hubalek,Gunda Pristauz,Thomas Bauernhofer,Holger Eidtmann,Wolfgang Eiermann,Guenther G. Steger,Werner Kwasny,Peter Dubsky,Gerhard Hochreiner,Ernst-Pius Forsthuber,Christian Fesl,Richard Greil +19 more
TL;DR: Long-term clinical efficacy including disease-free survival and disease outcomes in patients receiving anastrozole or tamoxifen with or without zoledronic acid is assessed, showing persistent benefits with zoledronics acid and support to adjuvant endocrine therapy with premenopausal patients.
Journal ArticleDOI
Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo- controlled trial
Michael Gnant,Georg Pfeiler,Peter Dubsky,Michael Hubalek,Richard Greil,Raimund Jakesz,Viktor Wette,Marija Balic,Ferdinand Haslbauer,Elisabeth Melbinger,Vesna Bjelic-Radisic,Silvia Artner-Matuschek,Florian Fitzal,Christian Marth,Paul Sevelda,Brigitte Mlineritsch,Günther G. Steger,Diether Manfreda,Ruth Exner,Daniel Egle,Jonas Bergh,Franz Kainberger,Susan Talbot,Douglas Warner,Christian Fesl,Christian F. Singer +25 more
TL;DR: Adjuvant denosumab 60 mg twice per year reduces the risk of clinical fractures in postmenopausal women with breast cancer receiving aromatase inhibitors, and can be administered without added toxicity.